Efficacy and safety of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
10.3760/cma.j.cn371439-20220330-00095
- VernacularTitle:博纳吐单抗治疗急性B淋巴细胞白血病的疗效和安全性
- Author:
Jialing LU
1
;
Huijuan HUANG
;
Dan LIU
;
Yanxin CHEN
;
Xiao MA
;
Depei WU
Author Information
1. 苏州大学附属第一医院血液科，苏州 215006
- Keywords:
Blinatumomab;
Bispecific antibody;
B-cell acute lymphoblastic leukemia;
Efficacy;
Safety
- From:
Journal of International Oncology
2022;49(8):494-498
- CountryChina
- Language:Chinese
-
Abstract:
Blinatumomab, as a novel bispecific antibody targeting CD19 and CD3, can induce T lymphocytes to precisely target CD19 positive B lymphocytes to apoptosis. At present, it is the only bispecific antibody approved for the treatment of hematological malignancies in China. Blinatumomab is effective in the treatment of newly diagnosed, relapsed/refractory, minimal residual disease positive patients with B-cell acute lymphoblastic leukemia (B-ALL) . It can improve the survival of the patients and is well tolerated. The further study of blinatumomab can provide theoretical basis and new ideas for induction therapy, salvage therapy and subsequent hematopoietic stem cell transplantation in patients with B-ALL.
